Format
Sort by

Send to

Choose Destination

Links from Protein

Items: 1 to 20 of 143

1.

Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.

Cumming JG, Debreczeni JÉ, Edfeldt F, Evertsson E, Harrison M, Holdgate GA, James MJ, Lamont SG, Oldham K, Sullivan JE, Wells SL.

J Med Chem. 2015 Jan 8;58(1):278-93. doi: 10.1021/jm501038s. Epub 2014 Oct 9.

PMID:
25255283
2.

The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.

Köpper F, Binkowski AM, Bierwirth C, Dobbelstein M.

Cell Cycle. 2014;13(6):884-9. doi: 10.4161/cc.28292. Epub 2014 Feb 21.

3.

The effect of functional MAPKAPK2 copy number variation CNV-30450 on elevating nasopharyngeal carcinoma risk is modulated by EBV infection.

Yang L, Liu B, Qiu F, Huang B, Li Y, Huang D, Yang R, Yang X, Deng J, Jiang Q, Zhou Y, Lu J.

Carcinogenesis. 2014 Jan;35(1):46-52. doi: 10.1093/carcin/bgt314. Epub 2013 Sep 20.

4.

A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.

Liu B, Yang L, Huang B, Cheng M, Wang H, Li Y, Huang D, Zheng J, Li Q, Zhang X, Ji W, Zhou Y, Lu J.

Am J Hum Genet. 2012 Aug 10;91(2):384-90. doi: 10.1016/j.ajhg.2012.07.003.

5.

Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.

Oubrie A, Kaptein A, de Zwart E, Hoogenboom N, Goorden R, van de Kar B, van Hoek M, de Kimpe V, van der Heijden R, Borsboom J, Kazemier B, de Roos J, Scheffers M, Lommerse J, Schultz-Fademrecht C, Barf T.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):613-8. doi: 10.1016/j.bmcl.2011.10.071. Epub 2011 Nov 3.

PMID:
22119462
6.

MK2 SUMOylation regulates actin filament remodeling and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation.

Chang E, Heo KS, Woo CH, Lee H, Le NT, Thomas TN, Fujiwara K, Abe J.

Blood. 2011 Feb 24;117(8):2527-37. doi: 10.1182/blood-2010-08-302281. Epub 2010 Dec 3.

7.

p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity.

Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, Wilson S, Koul HK.

Cancer Res. 2010 Jan 15;70(2):832-41. doi: 10.1158/0008-5472.CAN-09-2918. Epub 2010 Jan 12.

8.

Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.

Fujino A, Fukushima K, Namiki N, Kosugi T, Takimoto-Kamimura M.

Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):80-7. doi: 10.1107/S0907444909046411. Epub 2009 Dec 21.

PMID:
20057052
9.

The MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory response.

Saenz JB, Li J, Haslam DB.

Cell Microbiol. 2010 Apr 1;12(4):516-29. doi: 10.1111/j.1462-5822.2009.01414.x. Epub 2009 Nov 27.

10.

Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme.

Underwood KW, Parris KD, Federico E, Mosyak L, Czerwinski RM, Shane T, Taylor M, Svenson K, Liu Y, Hsiao CL, Wolfrom S, Maguire M, Malakian K, Telliez JB, Lin LL, Kriz RW, Seehra J, Somers WS, Stahl ML.

Structure. 2003 Jun;11(6):627-36.

11.

5-Lipoxygenase activation by MAPKAPK-2 and ERKs.

Werz O, Bürkert E, Fischer L, Szellas D, Dishart D, Samuelsson B, Rådmark O, Steinhilber D.

Adv Exp Med Biol. 2003;525:129-32. No abstract available.

PMID:
12751751
12.

Examination of the kinetic mechanism of mitogen-activated protein kinase activated protein kinase-2.

Schindler JF, Godbey A, Hood WF, Bolten SL, Broadus RM, Kasten TP, Cassely AJ, Hirsch JL, Merwood MA, Nagy MA, Fok KF, Saabye MJ, Morgan HM, Compton RP, Mourey RJ, Wittwer AJ, Monahan JB.

Biochim Biophys Acta. 2002 Jul 29;1598(1-2):88-97.

PMID:
12147348
13.

Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart.

Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, Vlahos CJ.

J Mol Cell Cardiol. 2001 Aug;33(8):1527-40.

PMID:
11448140
14.

p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes.

Craxton A, Shu G, Graves JD, Saklatvala J, Krebs EG, Clark EA.

J Immunol. 1998 Oct 1;161(7):3225-36.

15.
16.

The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor.

Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haegeman G, Cohen P, Fiers W.

EMBO J. 1996 Apr 15;15(8):1914-23.

17.

The primary structure of a human MAP kinase activated protein kinase 2.

Zu YL, Wu F, Gilchrist A, Ai Y, Labadia ME, Huang CK.

Biochem Biophys Res Commun. 1994 Apr 29;200(2):1118-24.

PMID:
8179591
19.

No more money for nursing education?

Sharp N.

Nurs Manage. 1990 Sep;21(9):24-5. No abstract available.

PMID:
2402373
20.

mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.

Herranz N, Gallage S, Mellone M, Wuestefeld T, Klotz S, Hanley CJ, Raguz S, Acosta JC, Innes AJ, Banito A, Georgilis A, Montoya A, Wolter K, Dharmalingam G, Faull P, Carroll T, Martínez-Barbera JP, Cutillas P, Reisinger F, Heikenwalder M, Miller RA, Withers D, Zender L, Thomas GJ, Gil J.

Nat Cell Biol. 2015 Sep;17(9):1205-17. doi: 10.1038/ncb3225. Epub 2015 Aug 17. Erratum in: Nat Cell Biol. 2015 Oct;17(10):1370.

Items per page

Supplemental Content

Write to the Help Desk